The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.

A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.

Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.

SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.